Boothbay Fund Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-101,000
| Closed | -$3.97M | – | 2273 |
|
|
2023
Q2 | $3.97M | Buy |
101,000
+60,713
| +151% | +$2.14M | 0.09% | 295 |
|
|
2023
Q1 | $980K | Sell |
40,287
-167,690
| -81% | -$3.67M | 0.02% | 993 |
|
|
2022
Q4 | $4.45M | Buy |
207,977
+27,908
| +15% | +$596K | 0.1% | 274 |
|
|
2022
Q3 | $3.23M | Buy |
+180,069
| New | +$2.36M | 0.08% | 362 |
|
|
2021
Q4 | – | Sell |
-21,694
| Closed | -$352K | – | 2337 |
|
|
2021
Q3 | $352K | Buy |
+21,694
| New | +$236K | 0.01% | 1252 |
|
|
2021
Q1 | – | Sell |
-15,942
| Closed | -$110K | – | 1866 |
|
|
2020
Q4 | $110K | Buy |
15,942
+3,435
| +27% | +$22K | ﹤0.01% | 1177 |
|
|
2020
Q3 | $71K | Buy |
+12,507
| New | +$59.6K | ﹤0.01% | 992 |
|
|
2019
Q4 | – | Sell |
-93,533
| Closed | -$105K | – | 1048 |
|
|
2019
Q3 | $105K | Hold |
93,533
| – | – | 0.01% | 698 |
|
|
2019
Q2 | $122K | Buy |
+93,533
| New | +$128K | 0.01% | 653 |
|
|
2019
Q1 | – | Sell |
-93,533
| Closed | -$112K | – | 919 |
|
|
2018
Q4 | $112K | Buy |
93,533
+51,325
| +122% | +$99.5K | 0.02% | 548 |
|
|
2018
Q3 | $100K | Sell |
42,208
-90,056
| -68% | -$224K | 0.01% | 713 |
|
|
2018
Q2 | $361K | Buy |
+132,264
| New | +$365K | 0.03% | 421 |
|
Boothbay Fund Management's ISEE Position: Q3 2023 in Review
Boothbay Fund Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 101,000 shares — an estimated $3.97M sold.
Boothbay Fund Management first reported a position in ISEE in Q2 2018 and held it in 12 quarters. The position peaked at $4.45M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Boothbay Fund Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Boothbay Fund Management sold 101,000 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $3.97M.
- Boothbay Fund Management first reported a position in IVERIC bio, Inc. Common Stock in Q2 2018 and held it in 12 quarters.
- Boothbay Fund Management's IVERIC bio, Inc. Common Stock position peaked at $4.45M in Q4 2022.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.